115 related articles for article (PubMed ID: 15155532)
1. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line.
Baumann Kubetzko FB; Di Paolo C; Maag C; Meier R; Schäfer BW; Betts DR; Stahel RA; Himmelmann A
Carcinogenesis; 2004 Oct; 25(10):1839-46. PubMed ID: 15155532
[TBL] [Abstract][Full Text] [Related]
2. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas.
Dong HY; Liu W; Cohen P; Mahle CE; Zhang W
Am J Surg Pathol; 2005 May; 29(5):687-92. PubMed ID: 15832095
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression.
Lagergren A; Manetopoulos C; Axelson H; Sigvardsson M
BMC Cancer; 2004 Nov; 4():80. PubMed ID: 15544702
[TBL] [Abstract][Full Text] [Related]
4. Independent regulation of the two Pax5 alleles during B-cell development.
Nutt SL; Vambrie S; Steinlein P; Kozmik Z; Rolink A; Weith A; Busslinger M
Nat Genet; 1999 Apr; 21(4):390-5. PubMed ID: 10192389
[TBL] [Abstract][Full Text] [Related]
5. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
Kanteti R; Nallasura V; Loganathan S; Tretiakova M; Kroll T; Krishnaswamy S; Faoro L; Cagle P; Husain AN; Vokes EE; Lang D; Salgia R
Lab Invest; 2009 Mar; 89(3):301-14. PubMed ID: 19139719
[TBL] [Abstract][Full Text] [Related]
6. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
Spengler BA; Lazarova DL; Ross RA; Biedler JL
Oncol Res; 1997; 9(9):467-76. PubMed ID: 9495452
[TBL] [Abstract][Full Text] [Related]
7. SOX2 promotes tumorigenicity and inhibits the differentiation of I-type neuroblastoma cells.
Yang S; Zheng J; Xiao X; Xu T; Tang W; Zhu H; Yang L; Zheng S; Dong K; Zhou G; Wang Y
Int J Oncol; 2015 Jan; 46(1):317-23. PubMed ID: 25333857
[TBL] [Abstract][Full Text] [Related]
8. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line.
Chambéry D; Mohseni-Zadeh S; de Gallé B; Babajko S
Cancer Res; 1999 Jun; 59(12):2898-902. PubMed ID: 10383152
[TBL] [Abstract][Full Text] [Related]
9. EBF-regulating Pax5 transcription is enhanced by STAT5 in the early stage of B cells.
Hirokawa S; Sato H; Kato I; Kudo A
Eur J Immunol; 2003 Jul; 33(7):1824-9. PubMed ID: 12811842
[TBL] [Abstract][Full Text] [Related]
10. Monoallelic expression of Pax5: a paradigm for the haploinsufficiency of mammalian Pax genes?
Nutt SL; Busslinger M
Biol Chem; 1999 Jun; 380(6):601-11. PubMed ID: 10430025
[TBL] [Abstract][Full Text] [Related]
11. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.
Yazawa T; Ito T; Kamma H; Suzuki T; Okudela K; Hayashi H; Horiguchi H; Ogata T; Mitsui H; Ikeda M; Kitamura H
Am J Pathol; 2002 Jul; 161(1):291-300. PubMed ID: 12107114
[TBL] [Abstract][Full Text] [Related]
12. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the regulation of Pax5 in lipopolysaccharide-activated B cells.
Yoo BS; Boverhof DR; Shnaider D; Crawford RB; Zacharewski TR; Kaminski NE
Toxicol Sci; 2004 Feb; 77(2):272-9. PubMed ID: 14600275
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers.
Palmisano WA; Crume KP; Grimes MJ; Winters SA; Toyota M; Esteller M; Joste N; Baylin SB; Belinsky SA
Cancer Res; 2003 Aug; 63(15):4620-5. PubMed ID: 12907641
[TBL] [Abstract][Full Text] [Related]
14. Roles for USF-2 in lung cancer proliferation and bronchial carcinogenesis.
Ocejo-Garcia M; Baokbah TA; Ashurst HL; Cowlishaw D; Soomro I; Coulson JM; Woll PJ
J Pathol; 2005 Jun; 206(2):151-9. PubMed ID: 15856526
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines.
Reed MF; Zagorski WA; Howington JA; Zilfou JT; Knudsen ES
Ann Thorac Surg; 2006 Jul; 82(1):249-53. PubMed ID: 16798224
[TBL] [Abstract][Full Text] [Related]
16. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
17. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
Tiacci E; Pileri S; Orleth A; Pacini R; Tabarrini A; Frenguelli F; Liso A; Diverio D; Lo-Coco F; Falini B
Cancer Res; 2004 Oct; 64(20):7399-404. PubMed ID: 15492262
[TBL] [Abstract][Full Text] [Related]
18. Morphologic conversion of a neuroblastoma-derived cell line by E6-mediated p53 degradation.
Gaitonde SV; Qi W; Falsey RR; Sidell N; Martinez JD
Cell Growth Differ; 2001 Jan; 12(1):19-27. PubMed ID: 11205742
[TBL] [Abstract][Full Text] [Related]
19. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer.
Sunaga N; Miyajima K; Suzuki M; Sato M; White MA; Ramirez RD; Shay JW; Gazdar AF; Minna JD
Cancer Res; 2004 Jun; 64(12):4277-85. PubMed ID: 15205342
[TBL] [Abstract][Full Text] [Related]
20. c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression.
Barr LF; Campbell SE; Diette GB; Gabrielson EW; Kim S; Shim H; Dang CV
Cancer Res; 2000 Jan; 60(1):143-9. PubMed ID: 10646866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
